Gilteritinib maintenance after allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute myeloid leukemia with FLT3-internal tandem duplication mutation

Gilteritinib maintenance after allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute myeloid leukemia with FLT3-internal tandem duplication mutation

Background: Patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with FLT3-Internal Tandem Duplication (ITD) mutation have a poor prognosis and high risk of relapse, even after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Prevention of disease relapse remains a...

Full description

Saved in:
Bibliographic Details
Main Authors: Chen Liang, Donglin Yang, Aiming Pang, Yi He, Rongli Zhang, Weihua Zhai, Sizhou Feng, Mingzhe Han, Suning Chen, Liping Dou, Yu Wang, Xiaojin Wu, Erlie Jiang
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Hematology
Subjects:
Acute myeloid leukemia
FLT3-ITD
hematopoietic stem cell transplantation
relapsed/refractory disease
FLT3 inhibitor
Gilteritinib
Online Access:https://www.tandfonline.com/doi/10.1080/16078454.2025.2509353
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/16078454.2025.2509353

Similar Items